HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

MY 5445

potential platelet aggregation inhibitor

Also Known As:

MY-5445

Networked: 4 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridazines: 11
    - Phthalazines: 7
      - MY 5445: 4

Experts

1.	Barrot, Michel: 2 articles (01/2022 - 09/2019)
2.	Bourguignon, Jean-Jacques: 2 articles (01/2022 - 09/2019)
3.	Megat, Salim: 2 articles (01/2022 - 09/2019)
4.	Salvat, Eric: 2 articles (01/2022 - 09/2019)
5.	Bohren, Yohann: 1 article (01/2022)
6.	Doridot, Stéphane: 1 article (01/2022)
7.	Freund-Mercier, Marie-José: 1 article (01/2022)
8.	Hugel, Sylvain: 1 article (01/2022)
9.	Journée, Sarah H: 1 article (01/2022)
10.	Lacaud, Adrien: 1 article (01/2022)

Related Diseases

1.	Hypersensitivity (Allergy) 09/01/2019 - "Both compounds showed the same efficacy on neuropathic allodynia as MY 5445, and thus produced a significant relief of mechanical hypersensitivity after 12 days of treatment." 01/01/2022 - "Mechanical hypersensitivity, evaluated using von Frey filaments, was relieved by sustained treatment with the non-selective PDEi theophylline and ibudilast (AV-411), with PDE4i rolipram, etazolate and YM-976, and with PDE5i sildenafil, zaprinast and MY-5445, but not by treatments with PDE1i vinpocetine, PDE2i EHNA or PDE3i milrinone. "
2.	Neoplasms (Cancer) 01/01/2020 - "Furthermore, we found that ABCG2 does not confer resistance to MY-5445 in human cancer cells. " 01/01/2020 - "We discovered that by inhibiting the drug transport function of ABCG2, MY-5445 potentiates drug-induced apoptosis in ABCG2-overexpressing multidrug-resistant cancer cells and resensitizes these cells to chemotherapeutic drugs. " 01/01/2020 - "Overall, our study revealed an additional action of MY-5445 to resensitize ABCG2-overexpressing multidrug-resistant cancer cells to conventional anticancer drugs, and this should be evaluated in future drug combination trials." 01/01/2020 - "MY-5445, a phosphodiesterase type 5 inhibitor, resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to cytotoxic anticancer drugs."
3.	Neuralgia (Stump Neuralgia) 09/01/2019 - "Selectivity profiles towards other PDE1-4 isoenzymes, water solubility and stability in acidic medium of the most potent PDE5 inhibitors were determined and the aminophthalazine 16h and its mimetic 41n (3-aminoindazole) were evaluated in comparison to MY 5445 (4b) in vivo in a model of neuropathic pain induced by sciatic nerve cuffing in mice (3 and 0.5 mg/kg, ip twice a day). "
4.	Hyperalgesia 09/01/2019 - "Both compounds showed the same efficacy on neuropathic allodynia as MY 5445, and thus produced a significant relief of mechanical hypersensitivity after 12 days of treatment."
5.	Glioblastoma (Glioblastoma Multiforme) 09/07/2021 - "The synergistic suppression of glioblastoma cell proliferation was achieved by combining PF-2545920 and MY-5445. " 09/07/2021 - "In particular, a combination comprising the MRP1 inhibitor reversan, PF-2545920 and MY-5445, all at low micromolar concentrations, afforded nearly complete inhibition of glioblastoma cell growth. " 09/07/2021 - "The PDE10A inhibitors PF-2545920, PQ10 and papaverine, the PDE3/4 inhibitor trequinsin and the putative PDE5 inhibitor MY-5445 potently decreased glioblastoma cell proliferation. "

Related Drugs and Biologics

1.	Rolipram
2.	Milrinone (Primacor)
3.	Theophylline (Theon)
4.	Etazolate
5.	Sildenafil Citrate (Viagra)
6.	YM 976
7.	ibudilast
8.	vinpocetine
9.	zaprinast
10.	9-(2-hydroxy-3-nonyl)adenine (EHNA)